The Technical AnalystExchange: TWO Sector: Healthcare Industry: Biotechnology
PharmaEngine, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.64% TWD92.80
America/New_York / 7 mai 2024 @ 01:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 13 329 mill |
| EPS: | 1.910 |
| P/E: | 48.59 |
| Earnings Date: | Jul 24, 2024 |
| SharesOutstanding: | 143.63 mill |
| Avg Daily Volume: | 1.025 mill |
| RATING 2024-05-06 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.40x |
| Company: PE 48.59 | sector: PE 34.77 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.84x |
| Company: PE 48.59 | industry: PE 58.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
TWD73.86 (-20.41%) TWD-18.94 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
TWD 90.19 - 95.41 ( +/- 2.82%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | TWD92.80 (-0.64% ) |
| Volume | 0.272 mill |
| Avg. Vol. | 1.025 mill |
| % of Avg. Vol | 26.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 4162.TWO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
4162.TWO
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.